ArticleBlood cancer journal2019
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.
Thomas Martin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled ittrialcites it